Session information

Session1-8

Lecture

[06] Session-2: Immuno-Oncology BC -Clinical advances

Sat. Jan 23, 2021 3:00 PM - 6:00 PM ROOM1 (Japan Standard Time)

Start: 15:00(JST) / 7:00(CET) / 0:00(CST)

+Add all to schedule

[Z06] Join the ZOOMWebinar [Session2]

Closed.
If you would like to watch the Day1 Lecture,
please go to the page below.
https://confit.atlas.jp/guide/event/kbccc2021/static/Day1Lecture

Introduction (3:00 PM - 3:05 PM)

3:05 PM - 3:30 PM

[1L11] Absolute Lymphocyte Count is a Predictor of Eribulin Efficacy for Advanced or Metastatic Breast Cancer in EMBRACE and Study 301

*Yasuo Miyoshi¹, Yuta Yoshimura², Kenichi Saito³, Kenzo Muramoto², Kenichi Nomoto³ (1. Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, 2. Eisai Co., Ltd., Koishikawa, Bunkyo-ku, Tokyo, Japan, 3. Eisai Inc., Woodcliff Lake, NJ, USA)

3:30 PM - 3:55 PM

[1L12] Novel approaches in the Immuno-Oncology therapy

*Rebecca Dent¹ (1.Head of Medical Oncology and Senior Consultant, National Cancer Centre Singapore)

3:55 PM - 4:20 PM

[1L13] Neoadjuvant therapy with Immuno-Oncology agents

*Giuseppe Curigliano¹ (1. European Institute of Oncology, IRCCS and University of Milano, Milano, Italy)

4:20 PM - 4:45 PM

[1L14] Antiangiogenesis and PD-1 blockade

*Qiang Liu¹ (1. TBC)

4:45 PM - 5:10 PM

[1L15] Alterlation of circulating immune profile in the Immuno-Oncology therapy

*Kosuke Kawaguchi¹ (1. Kyoto University)

Voting and discussion (5:10 PM - 6:00 PM)

▲